129.84
1.32 (1.03%)
| Previous Close | 128.52 |
| Open | 127.50 |
| Volume | 434,971 |
| Avg. Volume (3M) | 756,522 |
| Market Cap | 4,437,194,240 |
| Price / Earnings (TTM) | 51.12 |
| Price / Earnings (Forward) | 60.61 |
| Price / Sales | 9.38 |
| Price / Book | 10.16 |
| 52 Weeks Range | |
| Earnings Date | 24 Feb 2026 |
| Profit Margin | 10.03% |
| Operating Margin (TTM) | 19.12% |
| Diluted EPS (TTM) | 1.42 |
| Quarterly Revenue Growth (YOY) | 48.20% |
| Quarterly Earnings Growth (YOY) | 110.60% |
| Total Debt/Equity (MRQ) | 194.67% |
| Current Ratio (MRQ) | 9.10 |
| Operating Cash Flow (TTM) | 49.38 M |
| Levered Free Cash Flow (TTM) | -84.81 M |
| Return on Assets (TTM) | 4.21% |
| Return on Equity (TTM) | 22.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | TransMedics Group, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -2.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.60 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.03% |
| % Held by Institutions | 121.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 175.00 (Oppenheimer, 34.78%) | Buy |
| Median | 160.00 (23.23%) | |
| Low | 130.00 (Stifel, 0.12%) | Hold |
| Average | 158.00 (21.69%) | |
| Total | 5 Buy, 2 Hold | |
| Avg. Price @ Call | 130.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 09 Mar 2026 | 130.00 (0.12%) | Hold | 134.77 |
| Evercore ISI Group | 25 Feb 2026 | 170.00 (30.93%) | Buy | 131.85 |
| JP Morgan | 25 Feb 2026 | 149.00 (14.76%) | Hold | 131.85 |
| Needham | 25 Feb 2026 | 174.00 (34.01%) | Buy | 131.85 |
| Oppenheimer | 25 Feb 2026 | 175.00 (34.78%) | Buy | 131.85 |
| Piper Sandler | 25 Feb 2026 | 160.00 (23.23%) | Buy | 131.85 |
| Canaccord Genuity | 17 Dec 2025 | 148.00 (13.99%) | Buy | 121.93 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CORCORAN NICHOLAS | - | 147.00 | -2,966 | -436,002 |
| HERNANDEZ GERARDO | - | 147.33 | -7,611 | -1,123,593 |
| LOVELL STEPHANIE | - | 147.66 | -1,193 | -176,158 |
| RANGANATH ANIL P. | - | 147.00 | -864 | -127,008 |
| WEILL DAVID | - | 147.66 | -3,571 | -527,294 |
| Aggregate Net Quantity | -16,205 | |||
| Aggregate Net Value ($) | -2,390,055 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 147.33 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HERNANDEZ GERARDO | Officer | 04 Mar 2026 | Sell (-) | 7,236 | 147.66 | 1,068,468 |
| HERNANDEZ GERARDO | Officer | 04 Mar 2026 | Option execute | 7,236 | - | - |
| WEILL DAVID | Director | 04 Mar 2026 | Sell (-) | 3,571 | 147.66 | 527,294 |
| WEILL DAVID | Director | 04 Mar 2026 | Option execute | 3,571 | - | - |
| LOVELL STEPHANIE | Director | 04 Mar 2026 | Sell (-) | 1,193 | 147.66 | 176,158 |
| CORCORAN NICHOLAS | Officer | 02 Mar 2026 | Sell (-) | 2,966 | 147.00 | 436,002 |
| RANGANATH ANIL P. | Officer | 02 Mar 2026 | Sell (-) | 864 | 147.00 | 127,008 |
| HERNANDEZ GERARDO | Officer | 02 Mar 2026 | Sell (-) | 375 | 147.00 | 55,125 |
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts |
| 30 Dec 2025 | Announcement | TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 24 Dec 2025 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |